Kathy E. Wolski

Aug 22, 2024 | jamanetwork.com | Milind Y. Desai |Anjali T. Owens |Kathy E. Wolski

Key PointsQuestion  What is the longer-term efficacy of mavacamten in reducing the need for septal reduction therapy (SRT) in patients with obstructive hypertrophic cardiomyopathy (HCM)?

Apr 8, 2024 | jamanetwork.com | Steven Nissen |Kathy E. Wolski |Gerald Watts |Michael J. Koren

Key PointsQuestion  What is the safety and tolerability of zerlasiran and its effect on lipoprotein(a) serum concentrations? Findings  The trial enrolled 32 healthy participants and 36 patients with cardiovascular disease and lipoprotein(a) concentrations 150 nmol/L or greater. No serious adverse event occurred. The median change from baseline in lipoprotein(a) concentration 365 days after single doses for placebo, 300 mg, and 600 mg were 14%, −30%, and −29%.

Apr 8, 2024 | jacc.org | Steven Nissen |Howard Hutchinson |Kathy E. Wolski |Karol E. Watson

AbstractBACKGROUNDAlthough statins reduce adverse cardiovascular outcomes, less than half of eligible patients receive treatment. A nonprescription statin has the potential to improve access to statins. OBJECTIVESTo assess concordance between clinician and consumer assessment of eligibility for nonprescription statin treatment using a Technology Assisted Self-Selection (TASS) Web Application (Web App) and evaluate effect on low-density lipoprotein cholesterol (LDL-C) levels.

Nov 12, 2023 | jamanetwork.com | Steven Nissen |Kathy E. Wolski |Laura Michael

Key PointsQuestion  What is the safety and tolerability of lepodisiran, which is a short interfering RNA directed at hepatic production of apolipoprotein(a), and the effect on lipoprotein(a) serum concentrations at doses from 4 mg to 608 mg through 336 days (48 weeks) of follow-up? Findings  The trial enrolled 48 participants without cardiovascular disease and with lipoprotein(a) concentrations of 75 nmol/L or greater (or ≥30 mg/dL). A single serious adverse event occurred.